All In Biotech

Drug Trial Radar · NCT06054113

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

An Open-label, Multicenter, Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics (PK) of Blinatumomab in Chinese Pediatric Subjects With Relapsed or Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Actual

Start

Jul 23, 2024

Primary completion

Jan 6, 2026

Study completion Oct 14, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Sep 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 204 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of blinatumomab.

Conditions

  • B Precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia

Interventions

  • BlinatumomabDrug

    Administered via CIVI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Complete Remission (CR)Time frame: Up to 84 days
  2. Number of Participants with CR with Partial Recovery of Peripheral Blood Counts (CRh)Time frame: Up to 84 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Childrens Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Wuhan Childrens Hospital

    Wuhan, Hubei, China

  • Children's Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Shanghai Children's Medical Center

    Shanghai, Shanghai Municipality, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.